Cargando…
High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome
Antiphospholipid syndrome (APS) is characterized by arterial and venous thrombosis and/or morbid pregnancy, accompanied by persistent antiphospholipid antibody (aPL) positivity. However, due to the complex pathogenesis of APS and the large individual differences in the expression of aPL profiles of...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235516/ https://www.ncbi.nlm.nih.gov/pubmed/37275905 http://dx.doi.org/10.3389/fimmu.2023.1128245 |
_version_ | 1785052696565252096 |
---|---|
author | Liu, Qi Yang, Shuo Tan, Yuan Cui, Liyan |
author_facet | Liu, Qi Yang, Shuo Tan, Yuan Cui, Liyan |
author_sort | Liu, Qi |
collection | PubMed |
description | Antiphospholipid syndrome (APS) is characterized by arterial and venous thrombosis and/or morbid pregnancy, accompanied by persistent antiphospholipid antibody (aPL) positivity. However, due to the complex pathogenesis of APS and the large individual differences in the expression of aPL profiles of patients, the problem of APS diagnosis, prognosis judgment, and risk assessment may not be solved only from the antibody level. It is necessary to use new technologies and multiple dimensions to explore novel APS biomarkers. The application of next-generation sequencing (NGS) technology in diseases with a high incidence of somatic mutations, such as genetic diseases and tumors, has been very mature. Thus, we try to know the research and application progress of APS by NGS technology from genome, transcriptome, epigenome and other aspects. This review will describe the related research of NGS technology in APS and provide more reference for the deep understanding of APS-related screening markers and disease pathogenesis. |
format | Online Article Text |
id | pubmed-10235516 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102355162023-06-03 High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome Liu, Qi Yang, Shuo Tan, Yuan Cui, Liyan Front Immunol Immunology Antiphospholipid syndrome (APS) is characterized by arterial and venous thrombosis and/or morbid pregnancy, accompanied by persistent antiphospholipid antibody (aPL) positivity. However, due to the complex pathogenesis of APS and the large individual differences in the expression of aPL profiles of patients, the problem of APS diagnosis, prognosis judgment, and risk assessment may not be solved only from the antibody level. It is necessary to use new technologies and multiple dimensions to explore novel APS biomarkers. The application of next-generation sequencing (NGS) technology in diseases with a high incidence of somatic mutations, such as genetic diseases and tumors, has been very mature. Thus, we try to know the research and application progress of APS by NGS technology from genome, transcriptome, epigenome and other aspects. This review will describe the related research of NGS technology in APS and provide more reference for the deep understanding of APS-related screening markers and disease pathogenesis. Frontiers Media S.A. 2023-05-19 /pmc/articles/PMC10235516/ /pubmed/37275905 http://dx.doi.org/10.3389/fimmu.2023.1128245 Text en Copyright © 2023 Liu, Yang, Tan and Cui https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Liu, Qi Yang, Shuo Tan, Yuan Cui, Liyan High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome |
title | High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome |
title_full | High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome |
title_fullStr | High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome |
title_full_unstemmed | High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome |
title_short | High-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome |
title_sort | high-throughput sequencing technology facilitates the discovery of novel biomarkers for antiphospholipid syndrome |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235516/ https://www.ncbi.nlm.nih.gov/pubmed/37275905 http://dx.doi.org/10.3389/fimmu.2023.1128245 |
work_keys_str_mv | AT liuqi highthroughputsequencingtechnologyfacilitatesthediscoveryofnovelbiomarkersforantiphospholipidsyndrome AT yangshuo highthroughputsequencingtechnologyfacilitatesthediscoveryofnovelbiomarkersforantiphospholipidsyndrome AT tanyuan highthroughputsequencingtechnologyfacilitatesthediscoveryofnovelbiomarkersforantiphospholipidsyndrome AT cuiliyan highthroughputsequencingtechnologyfacilitatesthediscoveryofnovelbiomarkersforantiphospholipidsyndrome |